COVID-19 rapid guideline: delivery of systemic anticancer treatments - guidance (NG161)
The purpose of this guideline is to enable services to match the capacity for cancer treatment to patient needs if services become limited due to COVID-19 pandemic.
Source:
National Institute for Health and Care Excellence